Home > Dermatology > SPIN 2019 > Novel Considerations > Switching infliximab biosimilars safe in treating chronic plaque psoriasis

Switching infliximab biosimilars safe in treating chronic plaque psoriasis

Conference
SPIN 2019

Patients who switched between 2 different biosimilar infliximab products during treatment of chronic plaque psoriasis did not experience adverse events or change in severity [1]. In the study, 24 patients with psoriasis (12 of whom also had psoriatic arthritis) were switched from one infliximab biosimilar, CT-P13, to another, SB2. The patients, who had a previous exposure to CT-P13 of 23.2 (± 7.51) months, were then followed for 6 months after switching. Psoriasis Area and Severity Index (PASI) scores were measured at the time of the switch and at months 2, 4, and 6.

The investigators found that PASI scores at each measurement were substantially unchanged; mean scores at the time of the switch and at months 2, 4, and 6 were 0.67 (±1.38), 0.76 (±1.08), 0.71 (±0.93), and 0.42 (±0.62), respectively. In terms of adverse events (AEs), 2 infusion-related reactions, and 2 upper respiratory bacterial infections were observed in total. Despite the limited sample si...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on